The user is using a hair recovery treatment with 0.5 mg dutasteride, 5 mg biotin, 5% topical minoxidil, and dermarolling twice a week. They are considering using a 1.5 mm dermaroller and red light therapy.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
The user switched from minoxidil to a homemade 2-deoxy-d-ribose gel and noticed no hair fall after two weeks, despite stopping minoxidil. The gel includes water, 2-deoxy-d-ribose, vegetable glycerine, 2-phenoxyethanol, sodium alginate, and rosemary oil, and the user reports healthier-feeling hair.
Amino acids like lysine, methionine, and cysteine may help with androgenetic alopecia when taken in high doses along with a DHT blocker. Users discuss combining these with treatments like Minoxidil, finasteride, and RU58841.
The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.
The conversation is about finding a legitimate source for Procyanidin B2 or Apple Extract with a clear percentage of Procyanidin B2 for making a topical solution. The user reports thicker and darker body hair after taking Oral Apple Polyphenols extract.
The user experienced excessive bleeding during microneedling after consuming caffeine and THC, and is unsure if they should continue with the same routine. They are seeking advice on whether the bleeding is a cause for concern.
Topical aldactone is discussed for its effects on men's hair and muscles. The conversation explores its potential benefits and side effects compared to other treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.
A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
User uses dermaroller and minox for hair loss without success, considers adding Stemoxydine and mixing tretinoin with minox. Another user suggests a DHT inhibitor for sustainability.
The user is considering using Ruderma to maintain hair and is concerned about potential hair loss acceleration due to starting TRT. They are also inquiring about the use of minoxidil, RU58841, and a derma roller for hair maintenance.
A custom-made serum based on double-blind studies for AGA, which includes natural ingredients such as rosemary oil, procyanidin B-2, saw palmetto extract, curcuma aeruginosa, pumpkin seed oil and castor oil. The user has updated their recipe to include apple poly procyanidin B-2 4% concentration and other ingredients before topping it off with Pura d'or serum.
The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.
The user has high free testosterone and is still experiencing hair loss despite taking dutasteride and oral minoxidil for over three years. They are considering adding a topical anti-androgen like RU58841.
The user is experiencing breast tissue growth from taking dutasteride and minoxidil, and is considering reducing the dosage or stopping the medication. Suggestions include seeing an endocrinologist, using Raloxifene or Arimidex, and considering topical treatments or surgery if necessary.
The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.
The conversation is about finding a source for sterile dutasteride for mesotherapy to avoid side effects from oral 5AR blockers. The user is currently using microneedling and 0.01% topical dutasteride and plans to use transplants.
Travoprost may be more effective than minoxidil for hair growth and can be used alongside it, but its effectiveness is debated due to inconsistent dosing results. Travoprost is expensive and not widely used, with alternatives like latanoprost and bimatoprost being more accessible.
A 21-year-old male suffering from male pattern baldness is using topical finasteride and minoxidil, and oral minoxidil. His bloodwork shows normal DHT levels and slightly high testosterone, leading to discussions about the role of DHT sensitivity in hair loss, the potential impact of finasteride on his DHT levels, and the suggestion to proceed with oral finasteride due to his high testosterone.
A user reports high DHT levels despite taking finasteride and is concerned about inconsistent blood test results. They also take modafinil, vitamin D, and magnesium supplements.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
Despite using Dutasteride, RU58841, and Minoxidil, hair loss continues due to low testosterone levels from taking 15mg of testosterone weekly, which may not produce enough estrogen. Increasing testosterone dosage and stabilizing hormone levels might help address the issue.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
The user has high DHT levels despite using dutasteride, which may not be effective due to potential damage or spoilage. They are considering a hair transplant if DHT levels don't decrease after two years.